The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 05, 2018

Filed:

Nov. 06, 2015
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Honggang Cui, Lutherville, MD (US);

Andrew G. Cheetham, Charlottesville, VA (US);

Pengcheng Zhang, Baltimore, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/48 (2006.01); A61K 31/4745 (2006.01); A61K 31/337 (2006.01); A61K 38/04 (2006.01); A61K 33/24 (2006.01); A61K 47/55 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01);
U.S. Cl.
CPC ...
A61K 47/48246 (2013.01); A61K 33/24 (2013.01); A61K 47/551 (2017.08); A61K 47/64 (2017.08); A61K 47/6929 (2017.08);
Abstract

The present invention provides herein the design of monodisperse, amphiphilic anticancer drugs—which are now termed 'drug amphiphiles' (DAs)—that can spontaneously associate into discrete, stable supramolecular nanostructures with the potential for self-delivery (no additional carriers are needed). The quantitative drug loading in the resulting nanostructures is ensured by the very nature of the molecular design. The DA is a composition comprising: D-L-PEP; wherein D is 1 to 4 hydrophobic drug molecules which can be the same or different; L is 1 to 4 biodegradable linkers which can be the same or different; and PEP is a peptide that can spontaneously associate into discrete, stable supramolecular nanostructures. In an alternate embodiment, the DA composition also comprises a targeting ligand (T). Methods of making DA molecules, as well as their use in treatment of disease are also provided.


Find Patent Forward Citations

Loading…